- This Week in Biopharma Deals, by biodealroom
- Posts
- Strategic acquisitions and collaborations dominate the week
Strategic acquisitions and collaborations dominate the week
Week 41 Deals (2024)
Deal of the Week: Recordati & Sanofi (Source)
Recordati strengthens rare diseases portfolio with global rights to Enjaymo
Structure: Acquisition of global rights to Enjaymo (sutimlimab), a treatment for cold agglutinin disease (CAD)
Date Announced: October 4, 2024
Total Deal Value: €1.2 billion
Upfront Cash: €800 million
Milestones: €400 million in potential regulatory and sales-based milestones
Royalties: Undisclosed
Other Terms: Recordati will take over all commercial and manufacturing responsibilities for Enjaymo globally
Notable Deals
Bayer & MOMA Therapeutics (Source)
Bayer partners with MOMA Therapeutics on oncology treatments
Structure: Collaboration and license agreement focused on developing precision oncology therapies targeting molecular machines
Date Announced: October 8, 2024
Total Deal Value: $1 billion
Upfront Cash: $150 million
Milestones: $850 million in development, regulatory, and commercial milestones
Royalties: Tiered royalties on future sales
Innovent & ASK Pharm (Source)
Innovent and ASK Pharm collaborate on third-generation EGFR TKI for lung cancer
Structure: Strategic collaboration for the development and commercialization of Limertinib, a third-generation EGFR TKI for lung cancer treatment in China
Date Announced: October 7, 2024
Total Deal Value: $700 million
Upfront Cash: $100 million
Milestones: $600 million in potential milestones based on development and sales achievements
Astellas & AviadoBio (Source)
Astellas secures exclusive option for gene therapy AVB-101 targeting frontotemporal dementia
Structure: Exclusive option and license agreement for AVB-101, a gene therapy targeting frontotemporal dementia and other neurological indications
Date Announced: October 8, 2024
Total Deal Value: $500 million
Upfront Cash: $50 million
Milestones: $450 million in development and commercial milestones
Boehringer Ingelheim & Circle Pharma (Source)
Boehringer Ingelheim teams up with Circle Pharma to develop novel precision cancer therapies
Structure: Research collaboration to develop macrocycle-based precision therapies for cancer treatment
Date Announced: October 9, 2024
Key Terms: Boehringer Ingelheim will leverage Circle Pharma's macrocycle platform to identify novel compounds targeting specific cancer pathways. Financial terms were not disclosed.
Qinotto & Lilly (Source)
Qinotto and Lilly enter research collaboration for novel pain therapeutics
Structure: Research collaboration and license agreement focused on discovering novel pain therapeutics using Qinotto's platform
Date Announced: October 8, 2024
Key Terms: Lilly will gain exclusive rights to develop and commercialize any resulting therapies. Financial terms were not disclosed.
Tonix Pharmaceuticals & X-Chem (Source)
Tonix Pharmaceuticals partners with X-Chem to develop broad-spectrum antivirals using AI
Structure: AI-driven collaboration focused on discovering broad-spectrum antiviral treatments
Date Announced: October 8, 2024
Key Terms: X-Chem will apply its AI technology to identify potential antiviral candidates. Financial terms were not disclosed.